FATE — Fate Therapeutics Balance Sheet
0.000.00%
- $150.14m
- -$128.93m
- $13.63m
- 22
- 31
- 19
- 12
Annual balance sheet for Fate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 483 | 616 | 436 | 315 | 279 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.51 | 8.68 | 38.5 | 1.83 | 3.54 |
Prepaid Expenses | |||||
Total Current Assets | 494 | 633 | 502 | 332 | 292 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 99.4 | 162 | 176 | 159 | 111 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 622 | 921 | 706 | 506 | 441 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 85.6 | 81.3 | 114 | 39.1 | 38.5 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 238 | 243 | 222 | 138 | 122 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 384 | 679 | 484 | 368 | 319 |
Total Liabilities & Shareholders' Equity | 622 | 921 | 706 | 506 | 441 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |